Angiotensin-converting enzyme (ACE) inhibitors are known to cause angioedema. Most ACE inhibitor-induced angioedema cases describe swelling in the periorbital region, tongue, and pharynx. We describe a case of a 62-year-old female with presumed angioedema of the small bowel after more than a 2-year history of lisinopril use (with no recent changes in her dose of 40 mg orally twice daily). The patient presented with nausea and intermittent left middle and upper quadrant abdominal pain and denied history of angioedema or swelling with any medications or any history of abdominal pain. On physical examination, bowel sounds, liver, and spleen were normal. Laboratory tests revealed leukocytosis (15 400 per mm 3 ) and normal complement 1 esterase inhibitor levels. Abdominal computed tomography (CT) showed segmental small bowel thickening and edema with ascites and surrounding inflammatory changes. There was no lymphadenopathy, obstruction, or ileus. Two days after discontinuation of the lisinopril, the patient reported improvement in symptoms. The Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 7) between the development of angioedema of the small bowel and the lisinopril therapy. This case highlights the unique manner in which ACE inhibitorinduced angioedema may present. A review of published cases of ACE inhibitor-induced angioedema of the small bowel is provided.
Introduction
Angioedema is a swelling of the skin and mucous membranes that can lead to significant morbidity and mortality.
1,2 Currently, it is understood that angioedema is precipitated by an increase in histamine or bradykinin, leading to sudden capillary permeability and edema. In addition to causes such as allergic reactions, autoimmune disorders, and hereditary angioedema, angiotensin-converting enzyme (ACE) inhibitors have been shown to cause angioedema in 0.1% to 1% of patients receiving these medications. 2, 3 ACE inhibitors are proposed to precipitate angioedema by preventing the degradation of bradykinin. [2] [3] [4] [5] The vast majority of documented ACE inhibitor-induced angioedema cases describe swelling localized in the periorbital region, tongue, and pharynx. 5 Less commonly described in the literature is the presentation of angioedema of the gastrointestinal (GI) tract. In this case report, we describe a patient with presumed angioedema of the GI tract after more than a 2-year history of lisinopril use.
Case Report
A 62-year-old African American female presented with nausea and new intermittent left middle and upper quadrant abdominal pain that worsened with food intake and improved with bowel movements. She denied changes in weight or appetite, diarrhea, constipation, melena, hematochezia, and emesis. Her medical history included hypertension, atrial fibrillation, type II diabetes, seizures, iron deficiency anemia, chronic obstructive pulmonary disease, temporal arteritis, gastroesophageal reflux disease, and hiatal hernia. The patient denied any history of angioedema or swelling with any medications as well as any history of abdominal pain. The patient's medications prior to admission included lisinopril 40 mg orally twice a day, amlodipine 10 mg orally daily, metoprolol tartrate 12.5 mg orally twice a day, apixaban 5 mg orally twice a day, metformin 1000 mg orally twice a day, glipizide 2.5 mg extended release daily, simvastatin 20 mg orally at bedtime, levetiracetam 500 mg orally twice a day, ferrous sulfate enteric coated 325 mg orally daily with breakfast, ipratropium 0.02% nebulizers inhaled daily as needed, calcium carbonate 600 mg with vitamin D 400 units orally 2 tablets daily, docusate 100 mg orally twice a day, pantoprazole 40 mg orally twice a day, and folic acid 1 mg orally daily. Of note, the patient had been taking lisinopril 40 mg twice daily for over 2 years with no recent changes in dose.
On admission, the patient's vital signs were blood pressure 165/98, heart rate 97 beats/min, respiratory rate 20 breaths/min, and temperature of 98. 7 F with a pain rating of 10/10. Upon physical examination, palpation of the liver and spleen, auscultation of bowel sounds, and examination of the skin were all normal. Laboratory tests revealed a leukocytosis (15 400/mm 3 ) and normal complement 1 esterase inhibitor levels. All other laboratory results were unremarkable including a urinalysis and a serum creatinine which were within normal limits. A vasculitis work-up, consisting of antinuclear antibodies (ANA), ANCA, and complement components C3 and C4, was also negative. While the patient did not have any signs or symptoms of enteritis-given the lack of diarrhea-stool leukocytes, culture, and Clostridium difficile DNA polymerase chain reaction were ordered; all results were negative. An abdominal computed tomography (CT) showed segmental small bowel thickening and edema with associated ascites and surrounding inflammatory changes ( Figure 1 ). It was also noted that the patient did not have lymphadenopathy, obstruction, or ileus.
Based on all these findings, a diagnosis of angioedema of the small bowel was probable. At that time, lisinopril was discontinued and metoprolol tartrate was replaced by carvedilol 12.5 mg orally twice daily. Two days after discontinuation of the lisinopril, the patient reported improvement in symptoms; no other treatments (ie, corticosteroids, intravenous fluids, etc.) were used prior to recovery. The following day, the patient was discharged to home and instructed to follow up with her primary care physician within 1 week and the GI clinic in 2 months.
Discussion
Angioedema is an uncommon but potentially a dangerous side effect of ACE inhibitors. 2 In the process of inhibiting the production of angiotensin II, ACE inhibitors also prevent the breakdown of bradykinin. [2] [3] [4] [5] Bradykinin is an oligopeptide that induces vasodilation. Patients experiencing angioedema have been shown to have a 2 to 12 times increased level of bradykinin. 4 Since our patient's complement 1 esterase inhibitor level was within normal limits, the angioedema observed in this case is thought to be more likely due to an increased level of bradykinin rather than a hereditary etiology.
Since ACE inhibitor-induced angioedema of the small bowel is considered a diagnosis of exclusion, it is important to consider other possibilities. First, in our case, vasculitis was ruled out due to a normal skin examination, normal urinalysis and serum creatinine, and a negative vasculitis work-up (ANA, ANCA, C3, and C4). Second, isolated small bowel lymphoma should be considered but was excluded since our patient did not present with lymphadenopathy (on physical examination or CT scan), fever, night sweats, or weight loss. Third, while Crohn's disease may also be a possible diagnosis, it was unlikely in our patient without the presence of diarrhea, the lack of skipped segments, or terminal ileum involvement.
While most cases reported in the literature describe swelling limited to the periorbital and oropharyngeal regions, there have been reports of ACE inhibitor-induced angioedema of the bowel. A PubMed literature search was conducted with the terms "ACE inhibitor plus Angioedema plus (Gut or Bowel or Abdominal)." From this initial search, 46 articles were identified and screened for inclusion. Case reports were excluded if they did not occur in the United States (n ¼ 22), provided no radiologic evidence of bowel angioedema (n ¼ 2), provided no specific information about the presenting patient (n ¼ 1), or described no signs or symptoms of abdominal angioedema within the report (n ¼ 1). Twenty case reports describing 25 unique cases from the United States are summarized in Table 1. 6-25 Our patient possesses many of the characteristics most commonly seen in these previous cases (see Table 2 ): middle aged, African American, and female. Lisinopril was also the most commonly reported ACE inhibitor in these cases; however, this finding may have reflected more frequent physician prescribing for lisinopril rather than a higher intrinsic likelihood of causing angioedema of the small bowel relative to other ACE inhibitors. 26 As described in almost all reported cases of angioedema of the bowel, this case patient presented with abdominal pain and nausea. These symptoms can be attributed to the small bowel wall thickening and edema observed on imaging.
Although this was the first time our patient reported her symptoms, many of the published cases involve patients who presented multiple times with similar symptoms before ever receiving this diagnosis. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 27 One such patient underwent a partial small bowel resection before ACE inhibitor-induced angioedema was suspected. 27 As was the case with this patient, as well as with the other reported cases and our case, symptoms improved upon discontinuation of the ACE inhibitor. Only 13 of the 25 cases reported administration of additional agents for supportive management. Most of these supportive therapies included intravenous fluid replacement (n ¼ 6) 7, 12, 17, 21, 22, 25 and antiemetics, 6, 12, 22 antibiotics, 9, 16, 22 and acid suppressants (n ¼ 3 for each). 7, 24, 25 Time to recovery was only discussed in 20 of the case reports, while a majority of cases (n ¼ 15) than 48 hours, only 5 reported a recovery time of 3 or 4 days. 9, 10, 13, 17 Given the dangers of angioedema, our team decided that we could not ethically justify a rechallenge with lisinopril to confirm the causality.
In the calculation of the Naranjo adverse drug reaction probability scale 28 score, points were allocated for previous conclusive reports of ACE inhibitor-induced angioedema of the small bowel (1 point), the occurrence of angioedema of the small bowel after administration of the ACE inhibitor (2 points), improvement of symptoms after discontinuation of the ACE inhibitor (1 point), no alternative causes present for the angioedema of the bowel (2 points), and angioedema of the small bowel confirmed on CT scan (1 point). This resulted in a total score of 7 points, which categorizes this adverse drug reaction as probable.
Conclusion
While it is certainly a rare phenomenon, our case and others like it to highlight the necessity of including angioedema of the bowel in differential diagnoses in patients receiving ACE inhibitors who present with nonspecific symptoms such as abdominal pain, nausea, vomiting, and ascites; this diagnosis should not be overlooked. This is especially true since discontinuation of the ACE inhibitor is an easy first step in therapy compared to the treatment of other possible diagnoses. The simple act of discontinuing the ACE inhibitor should be given consideration before invasive, irreversible measures are taken.
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